Fasenra

Fasenra (Benralizumab) is a subcutaneous injection used for managing severe eosinophilic asthma. This medication targets specific cells to help control symptoms and reduce flare-ups.

Fasenra is primarily used for the maintenance treatment of severe eosinophilic asthma in adults and children aged 12 years and older. It works by reducing the number of eosinophils, a type of white blood cell, which can help manage asthma symptoms and prevent exacerbations. Patients often wonder, 'What is Fasenra used for?' and the answer lies in its ability to provide long-term control for those with this specific type of asthma.

Common effects of Fasenra may include reactions at the injection site, such as redness, swelling, or itching. Some patients might experience headaches or fatigue. These effects are generally mild and temporary, but any persistent or severe symptoms should be discussed with a healthcare provider.

Fasenra should be used with caution in patients with a history of parasitic infections, as it may affect the body's ability to fight certain parasites. It is important to follow the prescribed dosage and administration instructions carefully. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Fasenra may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with a healthcare provider before starting Fasenra. Additionally, patients should be cautious when using other asthma medications concurrently, as this could potentially alter the effectiveness or safety of Fasenra.